146 related articles for article (PubMed ID: 31312936)
1. Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
Muñoz-Moreno L; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2020 Jun; 38(3):746-754. PubMed ID: 31312936
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.
Muñoz-Moreno L; Bajo AM; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2017 May; 446():59-69. PubMed ID: 28193499
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
5. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
[TBL] [Abstract][Full Text] [Related]
7. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E
Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946
[TBL] [Abstract][Full Text] [Related]
8. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
10. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
11. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
Rekasi Z; Czompoly T; Schally AV; Boldizsar F; Varga JL; Zarandi M; Berki T; Horvath RA; Nemeth P
Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3435-40. PubMed ID: 15728367
[TBL] [Abstract][Full Text] [Related]
12. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
[TBL] [Abstract][Full Text] [Related]
13. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
Humez S; Monet M; Legrand G; Lepage G; Delcourt P; Prevarskaya N
Endocr Relat Cancer; 2006 Mar; 13(1):181-95. PubMed ID: 16601287
[TBL] [Abstract][Full Text] [Related]
18. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
[TBL] [Abstract][Full Text] [Related]
19. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
20. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
